Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) will present at the Merriman Curhan Ford 6th Annual Investor Summit on November 10th at 3:40 pm (ET). The company's Chief Executive Officer, Ron Bentsur, will host the company's presentation. The conference is being held in New York City at the Sofitel New York. The company's presentation will be available via webcast through the Investors section of the company website. The presentaiton will be archived on the website following the presentation as well.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter.
About Keryx Biopharmaceuticals, Inc
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening including renal disease and cancer. The Company is developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is in Phase II clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). Keryx is developing KRX-0401 (perifosine), oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 is in Phase II clinical development for multiple tumor types.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
